Development of a Novel Bruton’s Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells

Weam Othman Elbezanti(Cooper Medical School of Rowan University), Manoj K. Pandey(Cooper Medical School of Rowan University)

bioRxiv (Cold Spring Harbor Laboratory)

March 10, 2022

10.1101/2022.03.10.483708

Cited by 0

Related Papers

Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway

|Blood|2007|246

Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1

|Molecular Pharmacology|2008|113

Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP‐1 in human multiple myeloma cells

|International Journal of Cancer|2009|106

A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis

|Experimental Hematology|2017|24

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

|Frontiers in Pharmacology|2024|4